NCT03216980|CompletedDMC
Loading search results
Sponsor study identifier
interventional
40
1 country
1
Study Start
May 15, 2017
Actual (reported)Primary Completion
March 31, 2021
Actual (reported)Study Completion
March 31, 2021
Actual (reported)Specific Aim #1: Examining the impact of mental health disorders (PTSD and GAD) on peripheral vascular function and sympathetic nervous system activity in young individuals. Specific Aim #2: Examining the impact of mental health disorders (PTSD and GAD) on peripheral hemodynamics and metabolic byproducts during small muscle mass exercise in young individuals. Specific Aim #3: Examining the impact of mental health disorders (PTSD and GAD) on exercise tolerance, peripheral hemodynamics and metabolic byproducts during large muscle mass exercise in young individuals.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
March 31, 2021
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
May 15, 2017
Actual (reported)June 27, 2017
Actual (reported)July 13, 2017
Actual (reported)March 31, 2021
Actual (reported)March 31, 2021
Actual (reported)Arm Vascular Function at Rest (Flow Mediated Dilation Test) and in Response to Exercise (Handgrip Exercise Test)
Change in Brachial Artery Dilation from Baseline Values
Before and Immediately After Intervention
Leg Vascular Function (Passive Leg Movement Test)
Change in Leg Blood Flow Values from Baseline
Before and Immediately After Intervention
Subjects will ingest an antioxidant cocktail containing 800 milligrams of alpha lipoic acid, 1 gram of vitamin C (ascorbic acid), and 400 milligrams of vitamin E (alpha tocopherol).
Subjects will ingest placebo (microcrystalline cellulose) pills.
Subjects will ingest an antioxidant cocktail containing 800 milligrams of alpha lipoic acid, 1 gram of vitamin C (ascorbic acid), and 400 milligrams of vitamin E (alpha tocopherol).
Subjects will ingest placebo (microcrystalline cellulose) pills.
Virginia Commonwealth University
Richmond, Virginia, 23298, United States
Ryan Garten, PhD
Virginia Commonwealth University
40 participants (actual enrollment reported by the registry).
First Submitted
June 27, 2017
First Posted
July 13, 2017
Study Start
May 15, 2017
Actual (reported)Introduction Seminar About Patient Participation and Treatment Options Decisional Preferences
Subjects will ingest an antioxidant cocktail containing 800 milligrams of alpha lipoic acid, 1 gram of vitamin C (ascorbic acid), and 400 milligrams of vitamin E (alpha tocopherol).
Subjects will ingest placebo (microcrystalline cellulose) pills.
Subjects will ingest an antioxidant cocktail containing 800 milligrams of alpha lipoic acid, 1 gram of vitamin C (ascorbic acid), and 400 milligrams of vitamin E (alpha tocopherol).
Subjects will ingest placebo (microcrystalline cellulose) pills.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Contact the study team to confirm eligibility.
Primary Completion
March 31, 2021
Actual (reported)Study Completion
March 31, 2021
Actual (reported)Last Updated
August 25, 2021
Record last verified: 2021-08
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: